These findings provide a fresh framework for understanding GPR6 function with a detailed basis for structure-based drug design, offering hope for improved future treatments of Parkinson's disease.
Researchers developed ProtGPS, an AI tool that predicts protein localization in cells and how mutations affect disease. The ...
Nature Medicine has been chronicling advances in medical technology and health care. To mark the journal’s 30th anniversary, each month ...
Drug discovery is a costly and time-intensive process, with binding free energy calculations between the potential drug ...
The innovative approach is based on the novel target leucyl-tRNA synthetase, belonging to the tRNA synthetase enzyme family on which Oxford Drug Design has developed a deep understanding. The new data ...
Oxford Drug Design, the Oxford-based AI drug discovery company, has announced further in vivo validation for its first-in-class cancer treatment approach. The company is developing novel treatments ...
Oxford Drug Design Ltd. has announced additional in vivo validation for its novel approach against cancer. The innovative approach, using generative AI capabilities, is based on the novel target ...
Recently, a joint research team developed a novel quantum-classical computing scheme for designing photochromic ...
News Medical on MSN18h
Insilico Medicine announces developmental candidate benchmarks and timelines for novel therapeutics discovered using generative AIInsilico Medicine pulls back the curtain on developmental timelines, highlighting a ~13 month average timeline to reach developmental candidate (DC) nomination across 22 programs. Insilico’s QPCTL ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback